Peptide-Based Nanoformulations for Combination Cancer Therapy
Combining therapeutic peptides with nanodelivery systems shows promise for improving cancer treatment by reducing side effects and increasing tumor targeting.
Quick Facts
What This Study Found
Peptide-based nanoformulations can enhance cancer treatment efficacy by improving tumor penetration, increasing circulation time, and reducing off-target toxicity when combined with conventional therapies.
Key Numbers
Covers: anticancer peptides, CPPs, tumor-targeting, peptidomimetics, peptide hormones, vaccines + chemo/immuno/radiation/hormone therapy
How They Did This
Narrative review surveying recent research on nanodelivery systems for peptide-based combination cancer therapies, including chemo-, immuno-, radiation, and hormone therapy combinations.
Why This Research Matters
Cancer treatment often suffers from severe side effects and drug resistance. Peptide nanoformulations offer a way to deliver targeted therapies more precisely, potentially improving outcomes while reducing harm.
The Bigger Picture
This represents the convergence of peptide science and nanotechnology in oncology — using the specificity of peptides and the delivery advantages of nanoparticles to create more effective, less toxic cancer treatments.
What This Study Doesn't Tell Us
As a review, it summarizes existing research without generating new data; many nanoformulation approaches discussed remain preclinical; clinical translation challenges are significant.
Questions This Raises
- ?Which peptide-nanoformulation combinations are closest to clinical translation?
- ?How do manufacturing scalability and cost affect the viability of these combination approaches?
- ?Can peptide nanoformulations overcome multidrug resistance in advanced cancers?
Trust & Context
- Key Stat:
- Multiple combination modalities Review covers peptide nanoformulations combined with chemo, immuno, radiation, and hormone therapy
- Evidence Grade:
- Comprehensive review of the field, but most studies discussed are preclinical; clinical evidence for peptide nanoformulations in cancer remains limited.
- Study Age:
- Published in 2020; the field of peptide nanoformulations for cancer is rapidly evolving with new formulations entering clinical trials.
- Original Title:
- Peptide-based combination nanoformulations for cancer therapy.
- Published In:
- Nanomedicine (London, England), 15(22), 2201-2217 (2020)
- Authors:
- Mehrotra, Neha, Kharbanda, Surender, Singh, Harpal
- Database ID:
- RPEP-04994
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
How do peptide nanoformulations improve cancer treatment?
They combine the targeting specificity of peptides with nanoparticle delivery to increase drug accumulation in tumors while reducing damage to healthy tissue.
What types of peptides are used in cancer nanoformulations?
Anticancer peptides, cell-penetrating peptides, tumor-targeting peptides, peptide vaccines, peptidomimetics, and peptide-based hormones are all being explored.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-04994APA
Mehrotra, Neha; Kharbanda, Surender; Singh, Harpal. (2020). Peptide-based combination nanoformulations for cancer therapy.. Nanomedicine (London, England), 15(22), 2201-2217. https://doi.org/10.2217/nnm-2020-0220
MLA
Mehrotra, Neha, et al. "Peptide-based combination nanoformulations for cancer therapy.." Nanomedicine (London, 2020. https://doi.org/10.2217/nnm-2020-0220
RethinkPeptides
RethinkPeptides Research Database. "Peptide-based combination nanoformulations for cancer therap..." RPEP-04994. Retrieved from https://rethinkpeptides.com/research/mehrotra-2020-peptidebased-combination-nanoformulations-for
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.